MoonLake Immunotherapeutics rises on collaboration with SHL Medical

MoonLake Immunotherapeutics

03/05/2023 16:40

** Shares of Switzerland-based MoonLake Immunotherapeutics 
 MLTX.O  rise 3.8% to $21.86
    ** Co signs a collaboration agreement with advanced drug
delivery solutions provider SHL Medical to develop an
autoinjector for MoonLake's sonelokimab
    ** Sonelokimab is an investigational antibody-derived
targeted therapy, currently in clinical development for a number
of inflammatory diseases
    ** Results from a mid-stage trial of the therapy in a type
of chronic skin condition called hidradenitis suppurativa is
expected around the end of June 2023 with final read-out by Q4
2023
    ** MLTX's stock up ~107% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))